Is the Oncology Bubble Ready to Pop?
This article was originally published in RPM Report
FDA Office of Oncology Drugs Director Richard Pazdur weighs in on the escalating prices of new cancer drugs.
You may also be interested in...
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.
NASEM is expected to issue a highly anticipated report in early 2021 on solutions to address Rx vial drug wastage.